United Therapeutics authorizes new $2 billion share buyback program
UTHR•United Therapeutics authorized a program to repurchase up to $2 billion of common stock through October 21, 2027. Its existing accelerated share repurchase transaction will not reduce the new authorization and is scheduled to end in the fourth quarter of 2026.
1. New repurchase authorization
United Therapeutics authorized a new program to buy back up to $2 billion of its common stock, available through October 21, 2027. The authorization will not be reduced by the company’s existing accelerated share repurchase transaction, initiated in September 2026, which is scheduled to end in the fourth quarter of 2026, subject to early termination or extension.
